The Wellness, Health News
Clinical
Trial results, drug approvals, biotech
29 Aug 2026NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures reveal that bowel cancer screening is detecting around 100 cases every week, but participation among people in their 50s remains notably low.
29 Aug 2026European Regulators Fast-Track Revolution Medicines Cancer Drug
European regulators have moved to expedite their assessment of a Revolution Medicines oncology drug, one of several notable regulatory developments reported in a July 2026 biotech roundup by STAT News.
- 29 Aug 2026
Bowel Screening Finds 100 Cancers a Week in People in Their 50s
New NHS England data covering April 2024 to March 2025 reveals that people in their 50s are less likely than other age groups to return bowel cancer screening kits, despite the programme detecting roughly 100 cancers per week among them.
- 29 Aug 2026
Three Biotech Rulings Reshape Drug Pipelines
A cluster of regulatory decisions is shifting the outlook for several drug developers, spanning oncology, autoimmune disease, and metabolic medicine.
- 28 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
Annual NHS bowel cancer screening figures for April 2024 to March 2025 show the programme is detecting approximately 100 cancers per week, even as participation among people in their 50s remains below that of older age groups.
- 28 Aug 2026
Biotech Regulatory Roundup: Three Drugs in Focus
A cluster of regulatory decisions in July 2026 has drawn attention to three drug candidates spanning oncology, autoimmune disease, and metabolic medicine.
- 28 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England figures show the bowel cancer screening programme detects roughly 100 cancers every week, yet participation among people in their 50s remains below desired levels.
- 28 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report that also covers an FDA clearance and emerging concerns around an oral GLP-1 candidate.
- 27 Aug 2026
Bowel Cancer Screening Gaps Found in People in Their 50s
New NHS England figures reveal that people in their 50s are among the least likely age groups to complete bowel cancer screening, despite the programme detecting roughly 100 cancers every week among those who do participate.
- 27 Aug 2026
Three Biotech Developments Shaping Drug Review Pipelines
Regulatory decisions and clinical data are shifting the outlook for several drug candidates, with European authorities granting accelerated review to a Revolution Medicines treatment and the FDA clearing an autoimmune therapy from Vera.
- 27 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 26 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 26 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
Annual NHS bowel screening figures for 2024–25 reveal that people in their 50s are among the least likely age groups to return their kits, even as the programme detects roughly 100 cancers every week.
- 26 Aug 2026
Three Biotech Regulatory Shifts Reshaping Drug Pipelines
A cluster of regulatory developments in mid-2026 is drawing attention across oncology, autoimmune disease, and metabolic medicine, according to reporting by STAT News.
- 25 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week in Over-50s
New NHS England figures covering April 2024 to March 2025 reveal that bowel cancer screening is detecting roughly 100 cancers per week among people in their 50s, even as participation rates in this age group lag behind older cohorts.
- 25 Aug 2026
Europe Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators announced plans to accelerate their review of a Revolution Medicines cancer drug, one of several notable regulatory developments reported by STAT News on July 8, 2026.
- 25 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly as 50s Lag
New NHS England figures covering April 2024 to March 2025 show that people in their 50s are among the least likely age groups to complete bowel cancer screening, with just over half of 54-year-olds participating.
- 25 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have moved to accelerate their assessment of a Revolution Medicines oncology drug, part of a broader week of notable regulatory shifts across the biotech sector.
- 24 Aug 2026
Three Biotech Regulatory Developments to Watch
A cluster of regulatory decisions is drawing attention across oncology, autoimmune disease, and metabolic medicine, according to a briefing from STAT News.
- 24 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England figures covering April 2024 to March 2025 reveal that bowel cancer screening is detecting approximately 100 cases per week, even as participation among people in their 50s remains notably low.
- 24 Aug 2026
Three Biotech Regulatory Developments in Brief
A cluster of regulatory decisions is shaping the near-term outlook for several drug developers, spanning oncology, autoimmune disease, and metabolic medicine.
- 23 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
Annual NHS England figures covering April 2024 to March 2025 show that roughly 100 bowel cancers are detected each week through screening, while participation among people in their 50s remains below levels seen in older age groups.
- 23 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report that also covers an FDA clearance and emerging concerns around an oral weight-loss pill.
- 22 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 show the bowel cancer screening programme is identifying roughly 100 cancers each week, even as uptake among those in their 50s lags behind older cohorts.
- 22 Aug 2026
European Regulators Fast-Track RevMed Cancer Drug Review
European regulators have agreed to expedite their assessment of a cancer drug developed by RevMed, according to a July 2026 report from STAT News covering several notable regulatory developments.
- 22 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England figures covering April 2024 to March 2025 reveal that bowel cancer screening is detecting approximately 100 cancers per week, yet uptake among people in their 50s remains below that of older age groups.
- 22 Aug 2026
European Regulators Fast-Track RevMed Cancer Drug Review
European regulators have agreed to expedite their assessment of a cancer drug from RevMed, one of several regulatory developments reported by STAT News on July 8, 2026.
- 21 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 reveal that people in their 50s are among the least likely age groups to complete bowel cancer screening, even as the programme detects roughly 100 cancers every week.
- 21 Aug 2026
Three Biotech Regulatory Shifts Reshaping Drug Pipelines
A cluster of regulatory decisions is reshaping near-term prospects for several drug developers, spanning oncology, autoimmune disease, and metabolic medicine.
- 21 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
Annual NHS bowel screening figures covering April 2024 to March 2025 reveal that approximately 100 cancers are being identified each week through the programme, even as participation rates among those in their 50s lag behind older age groups.
- 21 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News briefing covering several notable regulatory developments.
- 20 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England figures covering April 2024 to March 2025 show that people in their 50s are among the least likely age groups to complete bowel cancer screening, even as the programme detects roughly 100 cancers every week.
- 20 Aug 2026
Three Biotech Regulatory Shifts Reported in July 2026
A July 2026 STAT News roundup highlights three notable regulatory and clinical developments spanning oncology, autoimmune disease, and metabolic medicine.
- 20 Aug 2026
Three Biotech Developments Reshaping Drug Review
A cluster of regulatory and clinical developments is drawing attention across oncology, autoimmune disease, and metabolic medicine, according to a STAT News briefing published in July 2026.
- 19 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures show the bowel cancer screening programme is identifying roughly 100 cancers every week, even as participation among people in their 50s remains below desired levels.
- 19 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators moved to expedite their assessment of a Revolution Medicines oncology drug, one of several notable regulatory developments reported by STAT News on July 8, 2026.
- 19 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of a Revolution Medicines oncology candidate, according to a July 2026 STAT News report covering several notable regulatory developments.
- 18 Aug 2026
Bowel Screening Uptake Lags in 50s as 100 Cancers Found Weekly
Annual NHS England screening figures reveal that people in their 50s are among the least likely age groups to return bowel cancer testing kits, even as the programme identifies roughly 100 cancers every week.
- 18 Aug 2026
Three Biotech Developments Shaping Drug Review Pipelines
A cluster of regulatory decisions is drawing attention across oncology, autoimmune disease, and metabolic medicine, with outcomes ranging from expedited review to emerging safety questions.
- 18 Aug 2026
Bowel Screening Finds 100 Cancers Weekly in Over-50s
New NHS England figures reveal that bowel cancer screening is identifying roughly 100 cases per week among people in their 50s, even as participation rates in this age group trail behind older cohorts.
- 18 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
A cluster of regulatory decisions in July 2026 reshaped the near-term outlook for three biotechs, spanning oncology, autoimmune disease, and oral weight-loss medicine.
- 17 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators moved to expedite their assessment of a Revolution Medicines drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 17 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week in People in Their 50s
New NHS England figures show bowel cancer screening is detecting roughly 100 cancers per week among people in their 50s, even as participation rates in that age group trail behind older cohorts.
- 17 Aug 2026
Three Biotech Regulatory Shifts Reshaping Drug Pipelines
A cluster of regulatory developments is altering the near-term outlook for several drug candidates, spanning oncology, autoimmune disease, and metabolic medicine.
- 16 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 reveal that participation in bowel cancer screening remains notably low among people in their 50s, even as the programme identifies around 100 cancers every week.
- 16 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report that also covers an FDA clearance and emerging concerns around an oral GLP-1 candidate.
- 16 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 show the bowel cancer screening programme is detecting around 100 cancers per week, even as participation among people in their 50s remains comparatively low.
- 16 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of Revolution Medicines' cancer drug, according to a July 2026 STAT News briefing covering several concurrent regulatory developments.
- 15 Aug 2026
Bowel Screening Finds 100 Cancers Weekly as 50s Lag
New NHS England figures reveal that people in their 50s are among the least likely age groups to complete bowel cancer screening, despite the programme identifying approximately 100 cancers every week.
- 15 Aug 2026
Europe Fast-Tracks RevMed Cancer Drug Review
European regulators have agreed to expedite their assessment of a cancer drug from Revolution Medicines, according to a July 2026 STAT News report covering several concurrent regulatory developments.
- 15 Aug 2026
European Regulators to Fast-Track RevMed Drug Review
European regulators have moved to expedite their assessment of a Revolution Medicines drug, according to a July 8, 2026 STAT News report covering several regulatory and clinical developments.
- 14 Aug 2026
Bowel Screening Finds 100 Cancers a Week in People in Their 50s
New NHS England figures reveal that bowel cancer screening is detecting roughly 100 cancers per week among people in their 50s, yet participation in this age group continues to trail behind older cohorts.
- 14 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several concurrent regulatory developments.
- 14 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
Annual NHS bowel screening figures for 2024–25 reveal around 100 cancers are being detected each week through the programme, even as participation rates among those in their 50s lag behind older eligible adults.
- 14 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their review of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several concurrent regulatory developments.
- 13 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England data shows the bowel cancer screening programme is detecting roughly 100 cancers every week, yet participation among people in their 50s remains notably low.
- 13 Aug 2026
EU Expedites RevMed Drug Review in Biotech Roundup
European regulators have moved to fast-track their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 13 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England data covering April 2024 to March 2025 shows the bowel cancer screening programme is detecting roughly 100 cancers each week, yet participation among people in their 50s remains notably low.
- 13 Aug 2026
Three Biotech Regulatory Moves Shaping Drug Pipelines
A cluster of regulatory developments is reshaping near-term prospects for three biotechnology companies, spanning oncology, autoimmune disease, and metabolic medicine.
- 12 Aug 2026
EU Expedites RevMed Review; FDA Clears Vera Therapy
European regulators have moved to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report that also covers an FDA clearance and fresh concerns over an oral GLP-1 program.